The healthcare sector is booming and startups are the driving force behind the innovations that will affect the future of life on earth.
Running its last day on Thursday, Benzinga’s Healthcare Small Cap Conference provides investors and analysts with conversations and presentations from publicly traded companies and key figures behind this burgeoning sector.
Disrupting healthcare is the emerging sector of psychedelic medicine, which aims to bring substances like LSD and psilocybin mushrooms to the forefront of mental health treatments.
Below are some of the companies leading the “psychedelic renaissance,” which are participating in this important Benzinga event.
Cybin Inc. (NYSE: CYBN) is a company in the psychedelics sector, developing second-generation psychedelics for mental health and other indications.
The company was part of the Benzinga Global Small Cap Conference last May and since then its price has gone up over 50%, with a current stock price of $2.2.
Cybin became the first psychedelics company to go public on the NYSE in August, with a pipeline that includes a proprietary formulation of psilocybin (the active ingredient in so-called …